Johanna Simin
Karolinska Institutet, Stockholm, Sweden
Title: Menopausal hormone therapy and the risk of ovarian cancer: A Swedish population based matched-cohort study
Biography
Biography: Johanna Simin
Abstract
Statement of the Problem: Ovarian cancer has a poor prognosis, accounting for the most deaths among individuals with cancers of the female reproductive system, highlighting the need for preventive measures. Although ovarian cancer is relatively rare, Scandinavian countries have one among the highest incidence globally. Ovarian cancer shares some risk factors with breast cancer, and there is established evidence that menopausal hormone therapy (MHT), particularly combination therapy (estrogen + progestin, EP-MHT), increases the risk of invasive breast cancer.1, 2 However, the association with ovarian cancer is inconclusive.
Methodology & Theoretical Orientation: This large Swedish population based, group-level matched-cohort (1:3 ratio) study was based on the Swedish Prescribed Drug Registry and Patient Registry. All women ≥40 years, who received ≥1 prescription of systemic MHT during the study period, 2005-2012, were included. The risk of ovarian cancer was presented as multivariate adjusted odds ratios (OR) and 95% confidence intervals (CI), sub-grouped by the different MHT types, formulations, administration routes and modes. Women who underwent bilateral oophorectomy or salpingo-oophorectomy were excluded from analyses.